Showing 941-950 of 5550 results for "".
An Update on the Use of Trifarotene for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/an-update-on-the-use-of-trifarotene-for-the-treatment-of-acne/23267/Trifarotene is the first novel topical retinoid approved for the treatment of facial and truncal acne in 20 years.Comorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Collagen in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/collagen-atopic-dermatitis/27167/Kripa Ahuja, MS, and Peter Lio, MD, review a 2024 study from Szalsus et al. looking at the role of collagens in atopic dermatitis (AD).Curing the Blues: Resolution of the Tyndall Effect Through Removal of a Misplaced NASHA Filler with Hyaluronidase
https://practicaldermatology.com/topics/general-topics/PD0509_11-php/22833/Implantation of NASHA fillers too superficially can produce the Tyndall effect. Besides aesthetic elegance, longevity after injection and an excellent safety record, a significant advantage of NASHA fillers is that they are reversible when misplaced.Roflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulUnderstanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://practicaldermatology.com/programs/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.Physician Spotlight: Ellen Marmur, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-ellen-marmur-md/20581/Perspectives on head-to-toe beauty.High Risk SCC: What Factors Predict Recurrence and Metastasis?
https://practicaldermatology.com/topics/general-topics/PD1208_12-php/22609/Data shed light on risk factors associated with aggressive SCC, allowing dermatologists to identify and properly follow high-risk patients.GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal reGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d